Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) has been given an average rating of “Moderate Buy” by the ten ratings firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $53.29.
Several research firms recently issued reports on ASTH. Bank of America cut their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Truist Financial cut their price objective on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Barclays started coverage on Astrana Health in a report on Tuesday, April 1st. They set an “equal weight” rating and a $36.00 price target on the stock. Robert W. Baird cut their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Finally, Stifel Nicolaus cut their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th.
Read Our Latest Report on ASTH
Institutional Trading of Astrana Health
Astrana Health Stock Performance
NASDAQ ASTH opened at $27.08 on Friday. The stock’s fifty day moving average is $30.70 and its two-hundred day moving average is $34.90. The firm has a market capitalization of $1.52 billion, a P/E ratio of 20.83, a price-to-earnings-growth ratio of 1.37 and a beta of 1.00. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20.
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.09). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $620.39 million during the quarter, compared to analysts’ expectations of $628.11 million. During the same quarter in the prior year, the firm earned $0.31 EPS. Astrana Health’s revenue for the quarter was up 53.4% compared to the same quarter last year. On average, research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current year.
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
- Five stocks we like better than Astrana Health
- Buy P&G Now, Before It Sets A New All-Time High
- Top 5 Stocks Hedge Funds Are Buying Right Now
- There Are Different Types of Stock To Invest In
- Viking Holdings Posts Strong Q1, Eyes Growth Ahead
- Investing in Construction Stocks
- 2 Reasons Netflix’s 40% Rally Is Far From Over
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.